Advertisements

Tramadol acis

Quick links to important sections

Tramadol acis

Advertisements
Advertisements

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Tramadol acis

Quick Facts

Property Description
Active ingredient Tramadol Hydrochloride
Form Tablet, Capsule, Solution (Oral or Injectable)
Pharmacological class Opioid Analgesic
Common use Relief of pain
Origin Synthetic

Classification: Type, Composition, and Pharmacological Class

Tramadol acis is a pharmaceutical preparation whose core component is the active ingredient Tramadol Hydrochloride, which is scientifically classified as a synthetic, centrally acting opioid analgesic. This medication is manufactured by acis Pharma and is typically presented as a single-entity product. Its classification indicates its use for managing pain that is not adequately controlled by simpler, non-opioid medications.

The substance is chemically synthesized, meaning it is not derived from natural sources, and is an established agent for pain management. The product is commonly available in forms for oral administration, such as tablets and capsules, as well as a sterile aqueous solution for parenteral (injectable) use, offering flexibility in administration across different clinical needs.

General Purpose and Mechanism Principle

The general purpose of the medicine is to alleviate pain via a unique dual mechanism. Its action involves both a weak agonist effect on mu-opioid receptors and a distinct inhibition of the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. This combined pharmacological approach allows the drug to modulate the severity of pain perceived in the brain and spinal cord, providing a strong and comprehensive method of pain relief.

Advertisements

What side effects are possible with Tramadol acis?

The safety profile of Tramadol Hydrochloride is derived from regulatory classification and experience in clinical use, focusing strictly on the categories and frequencies of adverse effects documented in official government sources, such as the FDA and EMA.

Classification of Documented Adverse Reactions

Adverse reactions are classified by their reported frequency and the physiological systems affected. Reactions classified as Very Common (occurring in more than 1 in 10 individuals) include nausea and dizziness/vertigo. Common adverse reactions (1 in 100 to 1 in 10 individuals) primarily involve the nervous and gastrointestinal systems, such as somnolence (drowsiness), headache, constipation, vomiting, and dry mouth. Less frequent effects classified as Uncommon or Rare may affect the skin, cardiovascular, or respiratory systems.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight the potential for serious adverse reactions. These include the risk of life-threatening respiratory depression, especially at higher doses, and the potential for seizures (convulsions), which may be more likely when high doses are administered or with the use of other drugs that lower the seizure threshold. Serotonin Syndrome is also a documented, potentially life-threatening risk. As an opioid analgesic, the development of dependence, abuse, and misuse is an inherent, regulated safety concern, with withdrawal symptoms possible upon discontinuation after prolonged use.

Population and Exposure Safety Notes

Safety information specifies limitations and cautions for certain groups. Tramadol is contraindicated in children younger than 12 years. Use is generally not recommended in individuals with severe hepatic or renal impairment. Risk is noted to be higher in individuals identified as ultra-rapid metabolizers due to genetic factors. The frequency of side effects like nausea and CNS effects is documented to have a relationship with increasing dose.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Tramadol Hydrochloride is a serious, life-threatening medical emergency documented in regulatory labeling that requires immediate intervention.

Documented Manifestations

The official overdose profile describes severe effects primarily targeting the central nervous system (CNS) and the respiratory system. Manifestations often include profound CNS depression, which can quickly lead to coma, severe somnolence, miosis (pinpoint pupils), and the risk of generalized convulsions or seizures. The most critical outcome is life-threatening respiratory depression and apnea (cessation of breathing). The potential for complications such as serotonin syndrome and cardiovascular collapse is also formally recognized in severe intoxication cases. Regulatory documents specifically note that accidental ingestion, particularly by children, carries a risk of fatal overdose.

Required Emergency Actions

Immediate emergency medical attention must be sought if an overdose is suspected or if signs like severe slowed breathing, extreme sleepiness, or inability to wake up occur. Treatment is officially defined as symptomatic and supportive, focused on stabilizing vital signs and maintaining breathing. Naloxone may be administered by medical personnel to counteract the respiratory depression caused by the opioid effect; however, the label notes it may not fully reverse all signs. Management procedures, such as gastric lavage or administration of activated charcoal, are described for timely intervention in a supervised healthcare setting.

Advertisements

Therapeutic Uses of Tramadol acis

What Tramadol acis Treats: Main Uses and Benefits

Tramadol is a therapeutic agent generally considered relevant for pain management, primarily reserved for addressing specific pain profiles that may require additional therapeutic support. Its use is centered on providing symptomatic relief for heightened, persistent, or nerve-related discomfort across several key clinical scenarios. The medication is commonly applied to address pain of moderate to severe intensity, especially when symptoms have not been sufficiently addressed by non-opioid medications.

The primary therapeutic role is to offer supportive relief that helps ease the overall symptom load when symptoms are difficult to tolerate, including acute pain, postoperative discomfort, and chronic conditions such as osteoarthritis or complex pain syndromes. It is commonly used when symptoms intensify and supportive relief is needed.

“The primary goal of this medication is to help patients cope more steadily with difficult episodes by easing the symptom burden.”

Quick Fact: Relief for Refractory and Intense Discomfort

Support During Acute and Chronic Pain Episodes

This analgesic is relevant for short-term support during episodes of intense, sudden-onset discomfort, such as pain experienced following surgical procedures. When pain is continuous, Tramadol may assist with symptom management to help support comfort, contributing to maintaining a sense of stability during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

The regulatory profile for Tramadol acis strictly defines who can and cannot use the medicine, primarily focusing on age, physical status, and organ function, as defined by official regulatory bodies.

Eligibility Scope

Category Official Regulatory Statement
Populations Allowed Generally established for use in adults 18 years and older under labeled conditions.
Absolute Contraindications Children younger than 12 years; children and adolescents younger than 18 years for post-operative pain after tonsillectomy or adenoidectomy. Patients with severe respiratory depression or acute, severe asthma, or those currently taking Monoamine Oxidase Inhibitors (MAOIs).
Major Restrictions Not recommended during breastfeeding or for prolonged use during pregnancy. Use is avoided in cases of severe renal impairment (creatinine clearance < 30 mL/min) and severe hepatic impairment. Use requires greater caution in older adults over 75 years and those with a history of seizures or uncontrolled epilepsy.

Eligibility Classifications

Eligibility severity classification (as defined in official documents): Contraindicated, Avoid Use, Not Recommended, Use with Caution.

Eligibility-context constraints (as defined in official documents): Age-dependent (e.g., < 12 years), Metabolic-dependent (e.g., ultra-rapid metabolizers), and Physiological status-dependent (e.g., severe organ impairment).

Resulting Eligibility Structure

Regulatory documents establish absolute contraindications that strictly exclude specific populations, notably all children under 12 years of age and those with critical respiratory compromise. Furthermore, eligibility is made conditional for individuals with organ function challenges or specific vulnerabilities like seizure history, defining mandatory constraints for use.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information classifies Tramadol acis interactions into several critical domains, defining strict use conditions and prohibitions.

Mandatory Restrictions

Classification Interacting Agents (Examples) Constraint Regulatory Basis
Contraindicated Monoamine Oxidase Inhibitors (MAOIs), Alcohol Must not be used concurrently. MAOIs require a mandatory 14-day separation period. FDA/SmPC
Not Recommended Carbamazepine, Opioid Agonists-Antagonists Carbamazepine significantly reduces analgesic effect; Opioid Agonists-Antagonists may reduce efficacy. FDA/HPRA

Pharmacokinetic and Pharmacodynamic Interactions

  • Central Nervous System (CNS) Depressants: Co-administration with substances such as benzodiazepines, general anesthetics, or other opioids may lead to a profound pharmacodynamic additive effect, resulting in severe sedation and life-threatening respiratory depression.
  • Serotonergic Drugs: Concomitant use with SSRIs, SNRIs, or Triptans enhances the risk of Serotonin Syndrome due to combined serotonergic activity.
  • CYP Enzyme Interference: CYP2D6 Inhibitors (e.g., Fluoxetine, Quinidine) increase the parent drug (Tramadol) exposure while decreasing the active metabolite (M1) exposure. CYP3A4 Inducers (e.g., Carbamazepine, St. John's Wort) may decrease Tramadol's effectiveness by speeding up metabolism.
  • Anticoagulants: Reports indicate that Tramadol interaction with Warfarin and other Coumarin derivatives can result in an alteration of the anticoagulant effect, specifically leading to an elevation of the International Normalized Ratio (INR).

Population-Specific Notes

Regulatory documents highlight that elderly, cachectic, or debilitated patients face an increased vulnerability to life-threatening respiratory depression when Tramadol is co-administered with other CNS depressants.

Advertisements

Mechanism of Action

Tramadol operates through a dual mechanism of action within the central nervous system, targeting both opioid receptors and monoamine neurotransmitter transporters.

Opioid Receptor Interaction

The parent compound and, more significantly, its active metabolite O-desmethyltramadol (M1), act as agonists at the mu-opioid receptor (MOR). MORs are G protein-coupled receptors. Their activation triggers an inhibitory cascade, typically involving the inhibition of adenylyl cyclase, which decreases the intracellular concentration of cyclic adenosine monophosphate (cAMP). This signaling alteration modulates neuronal excitability and the release of various neurotransmitters.


Monoamine Reuptake Inhibition

Tramadol, particularly the enantiomers, is an inhibitor of the reuptake of norepinephrine and serotonin at their respective sodium-dependent membrane transporters, the Norepinephrine Transporter (NET) and the Serotonin Transporter (SERT). This inhibition increases the synaptic concentration of these monoamines. The resulting enhanced noradrenergic and serotonergic activity in the descending inhibitory pathways of the spinal cord modulates the processing of afferent neuronal input. The combination of MOR agonism and monoamine reuptake inhibition results in system-level physiological consequences through the modulation of nociceptive signal transmission in the central nervous system.

Advertisements

Dosage and Administration Information

Tramadol acis administration is governed by a precise set of guidelines concerning its route, form, dose, and frequency. The medicine is available for both oral use, including immediate-release (IR) and prolonged-release (PR) tablets, and parenteral administration via intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection.

The standard adult dosing for immediate-release forms begins with 50 mg to 100 mg and is maintained with an individual dose of 50 mg to 100 mg administered every 4 to 6 hours. The total daily dose for IR forms must not exceed 400 mg. For the prolonged-release forms, the usual regimen is once daily, starting at 100 mg, with a maximum daily dose of 300 mg. Oral forms may be taken with or without food.

Special procedural constraints apply to different formulations. Prolonged-release tablets must be swallowed whole and must not be chewed, split, or crushed, as altering the form compromises the controlled release. Parenteral solutions are specified to be administered slowly, typically over several minutes for IV injections.

Dose adjustments are specified for particular populations. For patients over 75 years of age, the dosing interval for IR forms should be extended, and the maximum daily dose may be limited to 300 mg. Individuals with significant renal or hepatic impairment also require an extension of the dosing interval, often to 12 hours, with prolonged-release forms generally not being recommended. Regarding duration, the instruction is to use the medicine for the shortest time necessary, with long-term use requiring regular re-evaluation and gradual dose reduction (tapering) when discontinuation is necessary.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tramadol acis

Evidence for Use in Moderate to Severe Pain

Research explored the use of Tramadol acis in adults experiencing pain described as moderate to severe. Researchers examined this area primarily through short-term Randomized Controlled Trials (RCTs). These studies are designed to compare the study medication against a placebo (a pill with no active ingredient) or sometimes against other commonly used pain medications.

The research explored how symptoms changed in the observed populations by measuring changes in standard patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies where the average measured change in pain scores was noted when comparing the group receiving the study medication to the placebo group over the short duration of the trials. Evidence contributes to understanding symptom patterns observed during these controlled periods.

Evidence for Pain Associated with Osteoarthritis

For pain associated with conditions marked by functional limitations like Osteoarthritis (OA) of the knee or hip, research examined its use primarily in adult patient populations. Studies were conducted during periods of increased symptom activity and was evaluated in trials that specifically monitored outcomes reflecting daily functioning or activity level, such as walking ability and joint movement.

Trials documented changes in the WOMAC scale (evaluating pain and physical function). These findings provide insight into short-term changes in outcomes related to physical discomfort over the initial weeks of treatment. Studies contribute to the broader evidence landscape in the context of patients with pain linked to osteoarthritis.

Long-Term Studies and Follow-up Duration

The majority of clinical trials conducted for Tramadol acis have focused on short-term symptom changes, lasting for only a few weeks up to a few months. This means that long-term effects are not fully established by the controlled research. There is limited information for long-term outcomes regarding the sustained patterns of measured outcomes for pain or functional ability over many months or years.

What is Still Uncertain About Tramadol acis Evidence

It is important to acknowledge areas where the evidence base is incomplete. Evidence quality varies across studies, and sometimes findings were mixed regarding specific outcomes. Subgroup findings are uncertain, as many trials did not include enough people with specific comorbidities to draw firm conclusions. The data show patterns related to symptom measurement in the observed groups, but research does not determine whether an individual will respond similarly.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tramadol acis (FAQ)


Q: What kind of pain relief is Tramadol acis typically used for?

According to official product information, Tramadol is indicated for the management of pain that is considered moderate to moderately severe. It is intended for pain that requires treatment with an opioid analgesic because alternative treatments are not sufficient.


Q: What are the concerns about taking Tramadol acis with muscle relaxants?

Regulatory warnings advise that Tramadol should be used with caution if combined with other Central Nervous System (CNS) depressants, which includes muscle relaxants. Regulatory warnings indicate that this combination is associated with an increased risk of profound sedation, respiratory depression, and death.


Q: Can Tramadol acis affect blood pressure when taken with other medications?

Official documents indicate that changes in blood pressure, specifically low blood pressure (hypotension) or orthostatic hypotension, have been reported as uncommon side effects. Regulatory documents also note specific drug interactions, such as those that can occur with anticoagulants.


Q: Why does Tramadol acis sometimes have a controlled substance classification?

Tramadol is designated by governmental authorities (e.g., Schedule IV in the U.S.) as a controlled substance. This classification is due to its action as an opioid analgesic and the associated risk of abuse, misuse, and dependence.


Q: Is regular monitoring recommended for people taking Tramadol acis?

Regulatory documents describe that regular monitoring is emphasized throughout the course of treatment. This process is detailed for assessing the risk for addiction, abuse, and misuse. Monitoring is also necessary to watch for signs of respiratory depression, especially when starting the medicine or changing the dose.


Q: Are skin reactions or rashes listed as a known side effect of Tramadol acis?

Yes, official product information lists skin reactions, including rash, itching, and hives, as potential side effects. In rare instances, severe skin reactions, such as blistering or peeling of the skin, have also been reported in association with Tramadol.


Q: Where can I find authoritative information and official documents about Tramadol acis?

You can find authoritative information, such as the full Prescribing Information or patient Medication Guides, on websites run by governmental drug authorities. Examples of these sources include the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) MedlinePlus, or the European Medicines Agency (EMA).


Q: How does the action of Tramadol acis differ from non-opioid pain relievers?

Tramadol operates differently from most non-opioid pain relievers because it has a dual mechanism of action. It works in the central nervous system by combining a weak opioid effect on specific receptors with an action that increases the levels of the neurotransmitters norepinephrine and serotonin.


Q: How long does it usually take for Tramadol acis to start working?

For immediate-release oral forms of Tramadol, the onset of action is generally reported to occur within one hour of dosing. The maximum pain-relieving effect for this form is typically reached within two to three hours.


Q: How long can the pain-relieving effect of Tramadol acis be expected to last?

The duration of pain relief for immediate-release formulations is generally reported to last about six hours. Extended-release formulations, which are taken once daily, are specifically designed to provide pain relief over a 24-hour period.


Q: Can Tramadol acis be taken with common over-the-counter pain medicines?

Regulatory guidance often describes that Tramadol may be taken with common non-opioid over-the-counter pain relievers, such as paracetamol (acetaminophen), ibuprofen, or aspirin. However, use with any over-the-counter pain medicine that already contains an opioid, such as codeine, is discouraged in official documents.


Q: Is it safe to consume caffeine while using Tramadol acis?

Official regulatory warnings do not typically list a formal interaction or contraindication between Tramadol and caffeine. However, due to the drug’s effects on the central nervous system, regulatory documents note that general caution is prudent when combining it with any stimulant.


Q: What are the potential mental health side effects (e.g., changes in mood) of Tramadol acis?

In addition to physical effects, official documents list potential nervous system and mental health effects. These can include anxiety, nervousness, agitation, and general changes in mood. In rare instances, more severe mental health effects, such as hallucinations or depressive symptoms, have been reported.


Q: Does the efficacy of Tramadol acis decrease over time with continued use?

Yes, official documents acknowledge the development of pharmacological tolerance, which is the body’s physiological response to the medicine. Tolerance may result in the need for increasing doses to maintain the same level of pain relief over time.


Q: Does Tramadol acis pose a risk when operating machinery or driving?

Yes, official regulatory warnings advise that because Tramadol can cause side effects like dizziness, drowsiness, or visual disturbances, individuals should not drive or operate machinery. This caution is recommended until the effects of the medicine on the individual are established.


Q: Are allergic reactions listed among the known side effects?

Yes, official regulatory information confirms that allergic reactions, including serious reactions like anaphylaxis (hives, swelling of the face, difficulty breathing), are possible. Tramadol is strictly contraindicated in people who have a known allergy to the drug or other opioids.


Q: What should be done if a potential interaction with another medicine is suspected?

Official regulatory guidance states that if a potential interaction is suspected or a person begins experiencing unusual side effects, consultation with a healthcare provider immediately is required. This is necessary to discuss the current medications and the symptoms being experienced.

Advertisements

How should Tramadol acis be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict storage and disposal requirements for Tramadol, a controlled substance, to ensure product stability and prevent accidental ingestion.

Storage Conditions

  • Temperature and Environment: Store the medication in its original, tightly closed container at room temperature (often specified as below 30 C). Keep it away from excess heat and moisture; do not store in a bathroom. Injection or infusion solutions must generally not be refrigerated or frozen.
  • Child Safety: Due to the risk of fatal overdose, Tramadol must be stored securely, typically in a locked cabinet or lockbox, out of the sight and reach of children.
  • Handling: Specific formulations, such as extended-release tablets, must not be crushed, chewed, or dissolved to avoid an uncontrolled release of the drug. Ampoules must be used immediately upon opening, or within specified in-use stability periods (e.g., 48 hours after dilution).

Disposal Rules

  • Priority Method: Unused or expired medication should be disposed of via a government-authorized Drug Take-Back Program or collector.
  • Alternative Method: If a take-back program is unavailable, mix the medicine with an unpalatable substance (like coffee grounds or dirt) and place the mixture in a sealed container before discarding it in the household trash. As a last resort, some opioid medications are listed as safe to flush—consult the patient information leaflet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tramadol acis found in:

A-Z Index: